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OBJECTIVES: The introduction of targeted therapies for the treatment of metastatic 
renal cell carcinoma (mRCC) has greatly improved patient prognosis compared with 
interferon-alfa (IFN-A). As these therapies differ in clinical efﬁcacy and costs, eco-
nomic evaluations are needed to help decision makers allocate scarce resources. We 
evaluated the cost effectiveness of sunitinib versus bevacizumab plus IFN-A and tem-
sirolimus in patients with mRCC. METHODS: A cost-effectiveness model applying a 
third-party payer perspective was developed to simulate disease progression and sur-
vival using hazard ratios (HRs) for each treatment against IFN-A. The HRs were taken 
from latest data available for the pivotal phase III sunitinib trial and the phase II and 
III clinical trials of temsirolimus and bevacizumab plus IFN-A. Two comparative 
evaluations were made: (1) sunitinib versus bevacizumab  IFN-A in all patients and 
(2) sunitinib versus temsirolimus in patients with modiﬁed MSKCC poor-risk proﬁle 
only. Swedish clinical experts’ opinions and published data on routine follow-up, 
treatment-related adverse events, disease progression, best supportive care of termi-
nally-ill patients, and costs were used to complement clinical trial-based parameters 
and quality of life measures. Model outcomes included life-years (LY), progression-
free LY (PFLY), and quality adjusted LY (QALY) gained, treatment costs (2008 
Swedish krona [SEK]), and incremental cost-effectiveness ratios. RESULTS: Sunitinib 
was more effective (gains of 0.19 PFLY, 0.23 LY and 0.16 QALY) and less costly 
(SEK 307,879) than bevacizumab plus IFN-A over 10 years for all patients. In poor 
risk patients, sunitinib was more effective (gains of 0.12 PFLY, 0.08 LY and 0.07 
QALY) and more costly (SEK 18,024) than temsirolimus over 10 years. Sunitinib was 
cost-effective versus temsirolimus (SEK 265,044/QALY) compared to a threshold of 
SEK 500,000/QALY (a47,169/QALY). CONCLUSIONS: Sunitinib is a cost-effective 
alternative to bevacizumab plus IFN-A and temsirolimus for the ﬁrst-line treatment of 
mRCC in Sweden.
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OBJECTIVES: This study assessed the cost-effectiveness of Rituximab (R) in combina-
tion with Fludarabine and Cyclophosphamide (FC) as ﬁrst-line treatment for patients 
with Chronic Lymphocytic Leukemia (CLL) versus FC from the French Sickness Fund 
perspective. METHODS: A 3 health state (PFS, Progression and Death) Markov model 
with a 15 year life-time horizon was developed from the phase III CLL-8 trial (Hallek 
et al., 2008) with 2.2 years median follow-up. Utility values originated from a HTA-
study in CLL using the EQ-5D York Tariff. Resource use was estimated through 
published data and expert opinion. The analysis was restricted to direct medical costs 
including bone marrow transplantation and blood transfusions reported in CLL-8. 
The unit costs were obtained from French ofﬁcial sources. Costs were discounted at 
3%. Deterministic and probabilistic sensitivity analyses were performed and 95% 
conﬁdence intervals (CI) reported. RESULTS: Patients treated with FC compared with 
R-FC spent longer in progression (0.23 years (CI 0.05–0.44), the mean cost of sup-
portive care for progression represented the main cost driver. The totals per patient 
mean costs were higher for R-FC compared to FC alone due to the higher drug acquisi-
tion costs. However, this was partially offset by the reduction in the mean cost of 
supportive care for progression. Mean incremental life expectancy for patients treated 
with R-FC compared to FC was 1.21 years (CI 0.75–1.67), and when quality adjusted 
was 1.01 years (CI 0.61–1.44), at a cost of a13,585 and a16,226 per life year and 
quality adjusted life year gained, respectively. Univariate and probabilistic sensitivity 
analyses conﬁrmed the stability of the model and resulted in ICERs consistently below 
commonly cited willingness to pay thresholds. CONCLUSIONS: R-FC is a clinically 
effective in ﬁrst-line treatment of CLL patients as well as an economically optimal 
strategy in the management of CLL in France.
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OBJECTIVES: Compare the epidemiological and economic impact of accrued cross-
protection against oncogenic human papillomavirus (HPV) types beyond 16/18 pro-
vided by the bivalent vaccine (bi-v) vs. additional protection against non-oncogenic 
HPV types 6/11 of the quadrivalent vaccine (quadri-v), in France. METHODS: A 
lifetime Markov model calibrated to the French setting was developed to reﬂect 
the natural history of low- (evolving to genital warts—GWs) and high-risk HPV 
(evolving to cervical cancer—CC) infections, together with screening and vaccination 
effects, for a single age cohort of 370,000 14-year-old girls (70% coverage). Transition 
probabilities, costs and utility were estimated from literature, ofﬁcial tariffs and expert 
opinions. Vaccine efﬁcacy was obtained from recent phase III clinical trials (HPV-008 
for bi-v and FUTURE I-II for quadri-v), for comparable cohorts on pre-sexual debut 
population (infection naïve). Life-long protection was assumed for both vaccines. 
Number of Cervical Intraepithelial Neoplastic lesions (CIN), CC, CC deaths and 
GW, QALY and costs were estimated. Costs and outcomes (discounted at 3% and 
1.5% respectively) were compared from a societal perspective without indirect costs. 
RESULTS: Cross-protection of bi-v vs. quadri-v led to additional 29,587 CIN1, 2,928 
CIN2, 99 CC and 32 deaths prevented, while quadri-v prevented 14,302 GWs. It 
resulted in additional 556 QALY gained for bi-v The remaining CIN, CC and GW 
not prevented by vaccines would cost Ma39 for and Ma37 for At the current public 
prices of a111.82 for bi-v and a123,66 for quadri-v per dose, the vaccination program 
would cost Ma143 and Ma150 and be cost-effective at an estimated ICER/QALY of 
a10,611 and a11,833 respectively vs. the absence of vaccination. CONCLUSIONS: 
Both vaccines have different epidemiological impacts with an increased number of 
cancer cases prevented for bi-v, though in France, the economic impact of HPV mass 
vaccination is similar whatever the vaccine selected.
PCN73
COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO 
ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH 
HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED 
ON THE ABCSG-12 STUDY
Delea TE1, Taneja C1, Kaura S2, Chatzikou M3, Maiadiakis N4, Fagoulakis V4
1PAI (Policy Analysis Inc.), Brookline, MA, USA, 2Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA, 3Novartis (Hellas) S.A.C.I., Athens, Greece, 4National School of Public 
Health, Athens, Greece
OBJECTIVES: The ABCSG-12 trial demonstrated that adding zoledronic acid 4 mg 
IV q 6 months (ZOL) to endocrine therapy with goserelin 3.6 mg sc q 28 days plus 
tamoxifen 20 mg oral qd or anastrozole 1 mg oral qd (ET) in premenopausal women 
with hormone receptor positive (HR) early breast cancer (EBC) improves disease free 
survival versus ET alone. The objective of this study was to estimate the cost-effective-
ness of ZOL in this setting from the Greek health care system perspective. METHODS: 
A Markov model was used to project lifetime outcomes and costs of breast cancer 
care for premenopausal women with HR EBC receiving 3 yrs of ET or 3 yrs of ET 
plus ZOL. Cost-effectiveness was measured as the incremental cost per quality 
adjusted life year (QALY) gained. Probabilities of breast cancer recurrence were based 
on ABCSG-12. Probabilities and costs were from the published literature. Results were 
generated under 2 scenarios: 1) beneﬁts of ZOL persist to the 7 yr maximum follow-up 
in ABCSG-12 (trial beneﬁts) and 2) beneﬁts persist until recurrence or death (lifetime 
beneﬁts). RESULTS: Expected costs of 3 yrs of ZOL (medication and administration) 
were a1802. Under the trial beneﬁts scenario, costs of breast cancer recurrence were 
reduced by a58; ZOL was therefore projected to increase total costs by a1764. Under 
the lifetime beneﬁts scenario, costs of breast cancer recurrence were reduced by a1548; 
total expected lifetime costs were therefore increased by a273. QALYs gained with 
ZOL were 0.43 years under the trial beneﬁts scenario and 1.39 years under the lifetime 
beneﬁts scenario. Cost per QALY gained was a4102 and a196 under the two scenar-
ios, respectively. CONCLUSIONS: Adding ZOL to ET in premenopausal women with 
HR EBC is highly cost-effective from the Greek health care system perspective even 
under conservative assumptions regarding the duration of ZOL beneﬁts.
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OBJECTIVES: Zoledronic acid (ZOL) is efﬁcacious in reducing skeletal-related events 
(SREs) due to bone metastases in RCC patients. However limited information is avail-
able on its cost-effectiveness. This study evaluated the economic impact of ZOL 
therapy for RCC patients in France, Germany, and the UK. METHODS: The source 
for this analysis was a retrospective evaluation of a 9-month trial comparing ZOL vs. 
placebo with concomitant antineoplastic treatment in RCC patients with bone metas-
tases. A model was developed to simulate quality-adjusted life years (QALYs) and 
costs by integrating relevant assumptions and published information pertaining to 
SRE-incidence, costs, and effects on quality-of-life (QoL), mortality, drug and admin-
istration costs. It was assumed that patients experienced a 20 to 80% decrease in QoL 
for a month following an SRE, depending on the SRE type. SRE costs were based on 
diagnosis-related group (DRG) tariffs and the published literature. RESULTS: ZOL-
treated patients (n  27) experienced 1.07 fewer SREs, gained discounted QALYs 
(France and Germany  0.1563; the UK  0.1575), and incurred substantially lower 
discounted SRE-related costs (France  a4196, Germany  a3880, the UK  a3355) 
compared with patients who were on placebo (n  19). Inclusive of the treatment 
costs, ZOL savings per patient by country were as follows: France  a1358, Germany 
 a1223, and the UK  a719. According to probabilistic sensitivity analyses, ZOL 
therapy was predicted to result in cost savings in 67% to 77% of 1000 model simula-
tions, depending on the country. The cost per QALY gained was below the threshold 
of a30,000 in approximately 93% of the cases across all countries. CONCLUSIONS: 
ZOL is a cost-saving therapy for bone health management of advanced RCC patients 
in France, Germany, or the UK. This is because ZOL effectively prevents SREs, 
